ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30

ANAPTYSBIO, INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on May 12, 2026

$49.24+2.63 (+5.64%)

Close on Oct 19, 2026

Market cap: $2.28B
P/E (TTM): –
Dividend yield: –

ANAPTYSBIO, INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	235	91	17	10	63	75	8.00	5.00	10	17	18
Research & Development	136	164	132	89	98	80	99	56	29	15	17
General & Administrative	11	14	42	37	21	19	16	16	9.34	4.29	3.59
Operating Expenses	7.70	25	182	125	120	99	115	72	39	20	21
Operating Income	227	66	-164	-115	-57	-24	-107	-67	-29	-3.03	-3.32
Interest Expense	–	–	–	–	0	0	1.04	1.65	1.78	0.46	0.46
Interest & Investment Income	9.81	15	19	7.55	0.43	3.96	11	6.69	1.62	0.13	0.02
Other Non-Operating Income	-65	-35	0.79	-14	-0.98	3.95	9.94	4.87	-1.29	-1.23	-1.94
Gain (Loss) on Sale of Assets	–	–	0	0	0.02	0.10	–	0	0	0.00	0.00
Pretax Income	162	31	-164	-129	-58	-20	-97	-62	-30	-4.26	-5.27
Income Tax Expense	0.77	0.16	0.00	0.02	0	0	-0.15	-0.19	0	0	0.14
Income from Continuing Operations	162	31	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	-175	-176	–	–	–	–	–	–	–	–	–
Net Income	-13	-145	-164	-129	-58	-20	-97	-62	-30	-4.26	-5.41
Net Income to Common	–	–	–	–	–	–	-97	-62	-30	-4.26	–
EPS (Basic)(per share)	-0.46	-5.12	-6.08	-4.57	-2.11	-0.73	-3.60	-2.50	-1.52	-1.62	-2.12
EPS (Diluted)(per share)	-0.44	-4.92	-6.08	-4.57	-2.11	-0.73	-3.60	-2.50	-1.52	-1.62	-2.12
Shares Outstanding (Basic, Weighted)(shares)	29	28	27	28	27	27	27	25	20	2.64	2.55
Shares Outstanding (Diluted, Weighted)(shares)	30	30	27	28	27	27	27	25	20	2.64	2.55
EBITDA	227	66	-164	-114	-56	-23	-107	-66	-29	-2.79	-3.05

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 131.7%
Net margin: 82.4%
Return on equity, FY2025: -24.5%

Financial strength

Current ratio: 5.61
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 378.5%

Valuation

P/E ratio: –
Price to sales: 9.59
Price to book: 215.20
Dividend yield: –